An addition to the effect of treating co-infections on HIV-1 viral load. Modjarrad K, Vermund SH (2011) Lancet Infect Dis 11: 81 U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Althoff KN, Buchacz K, Hall HI, Zhang J, Hanna DB, Rebeiro P, Gange SJ, Moore RD, Kitahata MM, Gebo KA, Martin J, Justice AC, Horberg MA, Hogg RS, Sterling TR, Cescon A, Klein MB, Thorne JE, Crane HM, Mugavero MJ, Napravnik S, Kirk GD, Jacobson LP, Brooks JT, North American AIDS Cohort Collaboration on Research and Design (2012) Ann Intern Med 157: 325-35 Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, Van Loon K, Bonhoeffer S, Miralles GD, Montefiori D, Bartlett JA, Nixon DF (2001) Proc Natl Acad Sci U S A 98: 13288-93 Does severity of HIV disease in HIV-infected mothers affect mortality and morbidity among their uninfected infants? Kuhn L, Kasonde P, Sinkala M, Kankasa C, Semrau K, Scott N, Tsai WY, Vermund SH, Aldrovandi GM, Thea DM (2005) Clin Infect Dis 41: 1654-61 Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group. Spritzler J, Mildvan D, Russo A, Asthana D, Livnat D, Schock B, Kagan J, Landay A, Haas DW, Adult AIDS Clinical Trials Group (2003) Clin Infect Dis 37: 551-8 Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. Engels EA, Yanik EL, Wheeler W, Gill MJ, Shiels MS, Dubrow R, Althoff KN, Silverberg MJ, Brooks JT, Kitahata MM, Goedert JJ, Grover S, Mayor AM, Moore RD, Park LS, Rachlis A, Sigel K, Sterling TR, Thorne JE, Pfeiffer RM, North American AIDS Cohort Collaboration on Research and
Design of the International Epidemiologic Databases to Evaluate AIDS, North American AIDS Cohort Collaboration on Research and Design
of the International Epidemiologic Databases to Evaluate AIDS (2017) Clin Infect Dis 65: 636-643 Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla PG, Guest J, Samji H, Castagna A, d'Arminio Monforte A, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher HC, De Wit S, Burkholder GA, Teira R, Justice AC, Sterling TR, M Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle SM, Sterne J, Obel N, Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord (2014) Clin Infect Dis 58: 1312-21 An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy. Koethe JR, Jenkins CA, Shepherd BE, Stinnette SE, Sterling TR (2011) Clin Infect Dis 53: 952-60 Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, D'Arminio Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe FC, Dabis F, Fätkenheuer G, Sterling TR, del Amo J, Gill MJ, Crane HM, Saag MS, Guest J, Brodt HR, Sterne JA, Antiretroviral Cohort Collaboration (2014) Int J Epidemiol 43: 691-702 Effects on mortality of a nutritional intervention for malnourished HIV-infected adults referred for antiretroviral therapy: a randomised controlled trial. NUSTART (Nutritional Support for Africans Starting Antiretroviral Therapy) Study Team, Filteau S, PrayGod G, Kasonka L, Woodd S, Rehman AM, Chisenga M, Siame J, Koethe JR, Changalucha J, Michael D, Kidola J, Manno D, Larke N, Yilma D, Heimburger DC, Friis H, Kelly P (2015) BMC Med 13: 17 Testing and linkage of patients to early care. Vermund SH (2011) AIDS 25: 1547-8 Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. Tang J, Wilson CM, Meleth S, Myracle A, Lobashevsky E, Mulligan MJ, Douglas SD, Korber B, Vermund SH, Kaslow RA, REACH Study Group. Reaching for Excellence in Adolescent Care and Health (2002) AIDS 16: 2275-84 Early immunologic response and subsequent survival among malnourished adults receiving antiretroviral therapy in Urban Zambia. Koethe JR, Limbada MI, Giganti MJ, Nyirenda CK, Mulenga L, Wester CW, Chi BH, Stringer JS (2010) AIDS 24: 2117-21 Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. Lederman MM, McKinnis R, Kelleher D, Cutrell A, Mellors J, Neisler M, Cooney E, Haas DW, Haubrich R, Stanford J, Horton J, Landay A, Spreen W (2000) AIDS 14: 2635-42 Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting. Wester CW, Koethe JR, Shepherd BE, Stinnette SE, Rebeiro PF, Kipp AM, Hong H, Bussmann H, Gaolathe T, McGowan CC, Sterling TR, Marlink RG (2011) AIDS 25: 1471-9 An internationally generalizable risk index for mortality after one year of antiretroviral therapy. Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, Nattermann J, Lampe FC, Bucher HC, Sterling TR, Crane HM, Kitahata MM, May M, Sterne JA (2013) AIDS 27: 563-72 Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients. Phillips E, Gutiérrez S, Jahnke N, Yip B, Lima VD, Hogg RS, Harrigan PR, Montaner JS (2007) AIDS 21: 1561-8 Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. Haas DW, Zala C, Schrader S, Piliero P, Jaeger H, Nunes D, Thiry A, Schnittman S, Sension M, Protocol AI424-009 Study Group (2003) AIDS 17: 1339-49 Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. Kallianpur AR, Hulgan T, Canter JA, Ritchie MD, Haines JL, Robbins GK, Shafer RW, Clifford DB, Haas DW (2006) AIDS 20: 1503-13 Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. Haas DW, Arathoon E, Thompson MA, de Jesus Pedro R, Gallant JE, Uip DE, Currier J, Noriega LM, Lewi DS, Uribe P, Benetucci L, Cahn P, Paar D, White AC, Collier AC, Ramirez-Ronda CH, Harvey C, Chung MO, Mehrotra D, Chodakewitz J, Nguyen BY, Protocol 054/069 Study Teams (2000) AIDS 14: 1973-8 Peripheral blood mononuclear cell markers in antiretroviral therapy-naive HIV-infected and high risk seronegative adolescents. Adolescent Medicine HIV/AIDS Research Network. Douglas SD, Rudy B, Muenz L, Moscicki AB, Wilson CM, Holland C, Crowley-Nowick P, Vermund SH (1999) AIDS 13: 1629-35 A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV. Benson CA, van der Horst C, Lamarca A, Haas DW, McDonald CK, Steinhart CR, Rublein J, Quinn JB, Mondou E, Rousseau F, FTC-303/350 Writing Group (2004) AIDS 18: 2269-76 CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. Hulgan T, Raffanti S, Kheshti A, Blackwell RB, Rebeiro PF, Barkanic G, Ritz B, Sterling TR (2005) J Infect Dis 192: 950-7 Treatment of intestinal helminths does not reduce plasma concentrations of HIV-1 RNA in coinfected Zambian adults. Modjarrad K, Zulu I, Redden DT, Njobvu L, Lane HC, Bentwich Z, Vermund SH (2005) J Infect Dis 192: 1277-83 Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. Graham BS, McElrath MJ, Connor RI, Schwartz DH, Gorse GJ, Keefer MC, Mulligan MJ, Matthews TJ, Wolinsky SM, Montefiori DC, Vermund SH, Lambert JS, Corey L, Belshe RB, Dolin R, Wright PF, Korber BT, Wolff MC, Fast PE (1998) J Infect Dis 177: 310-9 Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study. Haas DW, Geraghty DE, Andersen J, Mar J, Motsinger AA, D'Aquila RT, Unutmaz D, Benson CA, Ritchie MD, Landay A, AIDS Clinical Trials Group (2006) J Infect Dis 194: 1098-107 CD4+ cell count and HIV load as predictors of size of anal warts over time in HIV-infected women. Luu HN, Amirian ES, Chan W, Beasley RP, Piller LB, Scheurer ME (2012) J Infect Dis 205: 578-85 Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. Skurnick JH, Palumbo P, DeVico A, Shacklett BL, Valentine FT, Merges M, Kamin-Lewis R, Mestecky J, Denny T, Lewis GK, Lloyd J, Praschunus R, Baker A, Nixon DF, Stranford S, Gallo R, Vermund SH, Louria DB (2002) J Infect Dis 185: 428-38 Rhinovirus-associated hospitalizations in young children. Miller EK, Lu X, Erdman DD, Poehling KA, Zhu Y, Griffin MR, Hartert TV, Anderson LJ, Weinberg GA, Hall CB, Iwane MK, Edwards KM, New Vaccine Surveillance Network (2007) J Infect Dis 195: 773-81 Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. Hulgan T, Shepherd BE, Raffanti SP, Fusco JS, Beckerman R, Barkanic G, Sterling TR (2007) J Infect Dis 195: 425-31 Incidence of clinical AIDS conditions in a cohort of homosexual men with CD4+ cell counts < 100/mm3. Multicenter AIDS Cohort Study. Bacellar H, Muñoz A, Hoover DR, Phair JP, Besley DR, Kingsley LA, Vermund SH (1994) J Infect Dis 170: 1284-7 Risk factors for squamous intraepithelial lesions on Pap smear in women at risk for human immunodeficiency virus infection. Klein RS, Ho GY, Vermund SH, Fleming I, Burk RD (1994) J Infect Dis 170: 1404-9 Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapy. Wellons MF, Ottinger JS, Weinhold KJ, Gryszowka V, Sanders LL, Edwards LJ, Gooding ME, Thomasch JR, Bartlett JA (2001) J Infect Dis 183: 1522-5 Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men. Schwartz LM, Castle PE, Follansbee S, Borgonovo S, Fetterman B, Tokugawa D, Lorey TS, Sahasrabuddhe VV, Luhn P, Gage JC, Darragh TM, Wentzensen N (2013) J Infect Dis 208: 1768-75 Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. Mildvan D, Bosch RJ, Kim RS, Spritzler J, Haas DW, Kuritzkes D, Kagan J, Nokta M, DeGruttola V, Moreno M, Landay A (2004) J Infect Dis 189: 1811-20 Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial. Haas DW, Fessel WJ, Delapenha RA, Kessler H, Seekins D, Kaplan M, Ruiz NM, Ploughman LM, Labriola DF, Manion DJ (2001) J Infect Dis 183: 392-400 Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. Lemly DC, Shepherd BE, Hulgan T, Rebeiro P, Stinnette S, Blackwell RB, Bebawy S, Kheshti A, Sterling TR, Raffanti SP (2009) J Infect Dis 199: 991-8 Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy. Shepherd BE, Jenkins CA, Rebeiro PF, Stinnette SE, Bebawy SS, McGowan CC, Hulgan T, Sterling TR (2010) Epidemiology 21: 698-705 Cross-cohort heterogeneity encountered while validating a model for HIV disease progression among antiretroviral initiators. Shepherd BE, Sterling TR, Moore RD, Raffanti SP, Hulgan T (2009) J Clin Epidemiol 62: 729-37 Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia. Sahasrabuddhe VV, Mwanahamuntu MH, Vermund SH, Huh WK, Lyon MD, Stringer JS, Parham GP (2007) Br J Cancer 96: 1480-3
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.